Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Morgan

Showing results (131-140 of 224) with videos related to

Pageof 23
Sort By:
Biorxiv : the Preprint Server for Biology|January 30, 2023
Impact of rare structural variant events in newly diagnosed multiple myelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Open Heart|June 22, 2023
Drugless and radiographer led: the start of a new era for CT coronary angiographyGareth Morgan-Hughes, Rebecca McNally, Christopher Gibbs Gibbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma PatientsS Peter Wu, Ruth M Pfeiffer, Inhye E Ahn, et al.
Leukemia & Lymphoma|December 5, 2008
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotypeBhawna Sirohi, Ray Powles, Seema Singhal, et al.
Ecancermedicalscience|February 14, 2018
Healthy living and cancer: evidence from UK BiobankPeter C Elwood, Alex Whitmarsh, John Gallacher, et al.
British Journal of Haematology|June 22, 2011
Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutationsCaroline L Alvares, Tino Schenk, Sanna Hulkki, et al.
Haematologica|October 26, 2010
Efficacy and outcome of autologous transplantation in rare myelomasCurly Morris, Mary Drake, Jane Apperley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myelomaK Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Pageof 23

Showing results (131-140 of 224) with videos related to

Sort By:
Pageof 23
Biorxiv : the Preprint Server for Biology|January 30, 2023
Impact of rare structural variant events in newly diagnosed multiple myelomaMonika Chojnacka, Benjamin Diamond, Bachisio Ziccheddu, et al.
Open Heart|June 22, 2023
Drugless and radiographer led: the start of a new era for CT coronary angiographyGareth Morgan-Hughes, Rebecca McNally, Christopher Gibbs Gibbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2016
Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma PatientsS Peter Wu, Ruth M Pfeiffer, Inhye E Ahn, et al.
Leukemia & Lymphoma|December 5, 2008
Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotypeBhawna Sirohi, Ray Powles, Seema Singhal, et al.
Ecancermedicalscience|February 14, 2018
Healthy living and cancer: evidence from UK BiobankPeter C Elwood, Alex Whitmarsh, John Gallacher, et al.
British Journal of Haematology|June 22, 2011
Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutationsCaroline L Alvares, Tino Schenk, Sanna Hulkki, et al.
Haematologica|October 26, 2010
Efficacy and outcome of autologous transplantation in rare myelomasCurly Morris, Mary Drake, Jane Apperley, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 16, 2011
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myelomaK Jack Ishak, J Jaime Caro, Mark T Drayson, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Pageof 23